A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia

Overview of attention for article published in Neuropsychopharmacology, November 2008

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

patent: 30 patents

guideline: 2 clinical guideline sources

Readers on

mendeley: 170 Mendeley

So far, Altmetric has seen 2 Guidelines that reference this research output.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

Clinical guideline published by World Federation of Societies of Biological Psychiatry (WFSBP) on 27 Jul 2012

The World Federation of Societies of Biological Psychiatry (WFSBP) is a non-profit organization founded in 1974, uniting 64 national societies and over 4,000 professionals globally. It aims to enhance knowledge in biological psychiatry through education and collaboration, fostering advancements in the field.

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

Clinical guideline published by British Association for Psychopharmacology (BAP) on 03 Feb 2011

The British Association for Psychopharmacology (BAP) focuses on advancing the field of psychopharmacology through evidence-based guidelines and consensus statements. They provide resources for professionals, including guidelines on various mental health topics, enhancing clinical decision-making.

This page shows the most recent posts that mention this research output. Click here to find out how to access more activity.